Home Science Oxford University Temporarily Halts Vaccine Trials Amid Suspected Side Effect In A...

Oxford University Temporarily Halts Vaccine Trials Amid Suspected Side Effect In A Participant From UK

Oxford-AstraZeneca COVID-19 vaccine has been put on a halt due to some "unexplained illness" detected in one of the recipients of the inoculation. 

Clinical trials of Oxford-AstraZeneca COVID-19 vaccine has been put on a halt due to some “unexplained illness” detected in one of the recipients of the inoculation. 

Stat News got a statement from AstraZeneca that confirmed the pause of the trials. In the report, a spokesperson from AstraZeneca stated that the break was triggered during a standard review process to permit evaluation of safety data. The spokesperson also noted that the company is conducting a thorough review of the single event to prevent prolonged delays.  

WireX August Download

BBC’s medical correspondent, Fergus Walsh tweeted: “Oxford University/AstraZeneca coronavirus vaccine trial put on hold while suspected adverse reaction independently investigated. My understanding is this is standard procedure when anyone who is on a vaccine trial is admitted to hospital, and their cause of illness is unknown.”

This is the second such halt in the vaccine trial. Experts believe that the tests are likely to resume in a few days.

Talking about the abruption, an Oxford University spokesperson stated:

In large trials, illnesses will happen by chance but must be independently reviewed to check this carefully.

Oxford-AstraZeneca vaccine’s Phase 3 trials commenced in the U.S. in late August. Phase 2/3 trials were initiated earlier in U.K., Brazil, and South Africa. It is suspected that the adverse reaction occurred during Phase 2/3 trials in the U.K. 

Oxford’s vaccine is one of the top contenders in the vaccine race and has consistently shown successful results in the earlier stages of clinical trials. In fact, the Serum Institute of India (SII) was also conducting the Phase 3 trials of this vaccine candidate, also called Covishield in India. On Monday, CEO of SII, Adar Poonawalla tweeted: “Proud and excited for the next few months and looking forward to the vaccine.”

In India, apart from Covishield, trials are underway for Bharat Biotech’s ‘Covaxin’, and Zydus Cadila’s ‘ZCOV-D’. 


WireX August Download

Muskan Bagrecha
Muskan is an undergraduate student pursuing a Bachelor's in Technology. With a zealous spirit for writing, she finds herself open to the vast realm of learning. She is an avid programmer with a keen interest in technology and science.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

This AI tool predicts onset of Alzheimer’s disease seven years before doctors

An Artificial Intelligence model, developed by IBM Research and pharmaceutical giant Pfizer, can predict Alzheimer’s seven years earlier than doctors with 70% accuracy. The...

Teardown video shows iPhone 12 and 12 Pro share same logic board, battery

A teardown video of the iPhone 12 and iPhone 12 Pro has confirmed the battery life of the models and given iOS lovers a...

Amid #BoycottChina, Chinese firms lead Indian smartphone market with 76% share

The Indian smartphone market showed an 8% growth in the third quarter of 2020, according to a market report by Canalys, a technology market...

Covid vaccine may not be safe in US

Vaccine stakeholders like health officials, hospitals, and pharmaceutical companies are taking stringent measures to prevent Covid vaccines from landing in the hands of criminals....

Recent Comments